Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma

Alexander A Azizi; Andreas V Hadjinicolaou; Carla Goncalves; Adam Duckworth; Bristi Basu

doi:10.3389/fonc.2020.570958

Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma

Front Oncol. 2020 Sep 25:10:570958. doi: 10.3389/fonc.2020.570958. eCollection 2020.

Authors

Alexander A Azizi¹, Andreas V Hadjinicolaou¹, Carla Goncalves¹, Adam Duckworth¹, Bristi Basu^{1

2}

Affiliations

¹ Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
² Department of Oncology, University of Cambridge, Cambridge, United Kingdom.

Abstract

Combined hepatocellular-cholangiocarcinoma (cHCC-ICC) is an uncommon and aggressive form of primary liver cancer. Currently, there are no international guidelines for optimal management. For localized tumors, radical resection represents the preferred treatment option, whereas for advanced tumors, systemic therapies recommended for intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC) are often selected. Emerging information from comparative cohort studies, genomic and transcriptomic data sets are starting to build a case for rationalized approaches to systemic treatment in the advanced setting specific to cHCC-ICC.

Keywords: Combined hepatocellular-cholangiocarcinoma; biphenotypic; cHCC-CCA; cHCC-ICC; genomics; primary liver cancer; systemic therapy.

Publication types

Review